31 Oct, 2024 Overview of cAPPricorn-1 Trial of Mivelsiran Presented at CTAD Conference 2024
Trial design and rationale for the global Phase 2 cAPPricorn-1 study of mivelsiran (ALN-APP) in patients with cerebral amyloid angiopathy (CAA), were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2024.